The SEC believed Bristol-Myers (BM) first engaged in channel stuffing (filling distribution channels with excess inventory to inflate sales and earnings figures) in the first quarter of 2000 through the fourth quarter of 2001. In addition to channel stuffing, BM also attempted an improper deal with Apotex Inc. and used "cookie jar" reserves to meet targets. The marketing programs "Double Double" and "Mega-Double" helped drive the need for channel stuffing. In total, BM paid $1.701 billion in fines and penalties for its fraudulent schemes. Revenue recognition frauds are a frequent problem for the SEC because they often result in large market capitalization drops and costly restatements.